Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Analytical Chemistry >  Standard >  Pharmaceutical Impurity Reference Standards >  2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonate

2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonate

Basic information Safety Supplier Related

2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonate Basic information

Product Name:
2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonate
Synonyms:
  • T8
  • ((2R,3R,5R)-3-(benzoyloxy)-
  • Gemcitabine impurity 2/2-Deoxy-2,2-difluoro-3,5-dibenzoate-1-methanesulfonate α-D-erythro-Pentofuranose
  • 2-Deoxy-2,2-difluoro-alpha-D-erythro-pentofuranose 3,5-dibenzoate 1-Methanesulfonate
  • ((2R,3R,5S)-3-(Benzoyloxy)-4,4-difluoro-5-((methyl-sulfonyl)oxy)tetrahydrofuran-2-yl)methyl benzo
  • -3-(Benzoyloxy)
  • -4,4-difluoro-5-((methylsulfonyl)
  • ((2R,3R,5S)-3-(Benzoyloxy)-4,4-difluoro-5-((methyl-sulfonyl)oxy)tetrahydrofuran-2-yl)methyl be
CAS:
134877-42-2
MF:
C20H18F2O8S
MW:
456.41
EINECS:
603-878-9
Product Categories:
  • Antineoplastic drug, difluorine nucleoside analog
Mol File:
134877-42-2.mol
More
Less

2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonate Chemical Properties

Boiling point:
588.4±50.0 °C(Predicted)
Density 
1.46
storage temp. 
2-8°C
Appearance
White to off-white Solid
More
Less

2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonate Usage And Synthesis

Uses

2-Deoxy-2,2-difluoro-3,5-dibenzoate-1-methanesulfonate α-D-erythro-Pentofuranose is an impurity of Gemcitabine (G305028), a potential anticancer agent.

Synthesis

124-63-0

1173824-58-2

134877-42-2

((2R,3R)-3-(Benzoyloxy)-4,4-difluoro-5-hydroxytetrahydrofuran-2-yl)methyl benzoate (4.14 g, 10.9 mmol) was dissolved in anhydrous dichloromethane (52 mL), anhydrous triethylamine (2.4 mL) was added and the solution was cooled to 0 °C. Methylsulfonyl chloride (1.23 mL, 15.8 mmol) was added slowly and dropwise with stirring. The reaction mixture was stirred at room temperature for 18 hours. Upon completion of the reaction, the mixture was transferred to a partition funnel and partitioned with methylene chloride (140 mL) and saturated sodium bicarbonate solution (56 mL). The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give an oily product as a mixture of isoheads (5.03 g, quantitative yield). The chemical shifts were analyzed by 19F NMR (CDCl3, 471 MHz) and were δ -107.770, -108.22, -120.65, -121.17, -122.21, -122.73, -123.76, -124.45.1H NMR (CDCl3, 500 MHz) data of the main isocaprolite (60%): δ 8.13-8.04 (m, 4H, benzoyl), 7.65-7.54 (m, 2H, benzoyl), 7.50-7.41 (m, 4H, benzoyl), 6.17 (d, J=5.6 Hz, 1H, H-1), 5.62 (dd, J1=4.2 Hz, J2=16.4 Hz, 1H, H-3), 4.91 (q, J= 3.9 Hz, 1H, H-4), 4.81-4.61 (m, 2H, H-5), 3.17 (s, 3H, CH3). 1H NMR (CDCl3, 500MHz) data of the minor isohead (40%): δ 8.13-8.04 (4H, m, benzoyl), 7.65-7.54 (m, 2H, benzoyl), 7.50-7.41 (m, 4H, benzoyl), 6.09 (d, J=6.4Hz, 1H, H-1), 5.98 (dt, J1 = 7.3 Hz, J2=15.0 Hz, 1H, H-3), 4.81-4.61 (m, 3H, H-4, H-5), 3.03 (s, 3H, CH3).13C NMR (CDCl3, 126 MHz) data: δ 40.09, 40.20 (CH3), 62.52, 63.08 (C-5), 69.61 (dd ), 71.04 (dd, J1C-F=15.7 Hz, J2C-F=26.0 Hz, C-3), 79.68, 79.75, 82.59 (C-4), 98.81 (dd, J1C-F=25.0 Hz, J2C-F=41.8 Hz, C-1), 99.52 (dd, J1C-F=25.0 Hz, J2C-F=41.8 Hz, C-1), 99.52 (dd, J1C-F=25.0 Hz, J2C-F=41.8 Hz C-1), 99.52 (dd, J1C-F=24.5Hz, J2C-F=46.3Hz, C-1), 120.61 (dd, J1C-F=253.5Hz, J2C-F=269.8Hz, C-2), 120.91 (dd, J1C-F=249.3Hz, J2C-F=276.3Hz, C-2) , 128.42, 128.58, 128.63, 128.70, 128.76, 128.79 (benzene ring), 129.18, 129.25 ('ipso' benzene ring), 129.76, 130.07, 130.14, 133.51, 133.63, 134.19, 134.26 (benzene ring), 164.89 , 165.03, 165.81, 165.90 (carbonyl).

References

[1] Synthesis, 1992, # 6, p. 565 - 570
[2] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 14, p. 4338 - 4345
[3] Patent: WO2009/61781, 2009, A1. Location in patent: Page/Page column 102-103
[4] Biochemistry, 2010, vol. 49, # 7, p. 1404 - 1417
[5] Patent: WO2005/95430, 2005, A1. Location in patent: Page/Page column 18

2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonateSupplier

shilang(zhuoli group)-pharma(nanjing) co.,ltd.
Tel
86-25-87797880,81,82 -809
Email
shilang@shilang-pharma.com
Beijing Lunarsun Pharmaceutical Co.,LTD.
Tel
86-10-64911848-8020.8010
Email
sales@lunarsun.com.cn
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696
Email
info@hanhongsci.com
Hunan Hui Bai Shi Biotechnology Co., Ltd.
Tel
0731-85526065 13308475853
Email
ivy@hnhbsj.com
Tongchuang Pharma(Suzhou). Co., Ltd.
Tel
0512-63263366 18912765016
Email
tongtf110@sina.com